LAS VEGAS--(BUSINESS WIRE)--Alzheimer’s drug Caprospinol (SP-233), from Samaritan Pharmaceuticals, Inc., (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, was cited by R&D Directions’ magazine’s seventh-annual list of 100 greatest investigational drugs in development by large and small companies throughout the world. According to R&D Directions, compounds on this list distinguish themselves as "innovative, first-in-class or clearly advanced compared with those on the market."
